RiverVest Venture Fund IV, L.P. - Oct 21, 2021 Form 3 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
10%+ Owner
Signature
/s/ Jay Schmelter, Manager of RiverVest Venture Partners IV, LLC
Stock symbol
XLO
Transactions as of
Oct 21, 2021
Transactions value $
$0
Form type
3
Date filed
10/21/2021, 08:40 PM
Next filing
Oct 26, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding XLO Series B Preferred Stock Oct 21, 2021 Common Stock 832K See footnote F1, F2, F3
holding XLO Series C Preferred Stock Oct 21, 2021 Common Stock 359K See footnote F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series B Preferred Stock and Series C Preferred Stock has no expiration date and are convertible at any time at the election of the holder without payment of further consideration. Each share of Series B Preferred Stock and Series C Preferred Stock will automatically convert into one share of Common Stock upon the closing of the Issuer's initial public offering.
F2 The shares held by RiverVest Venture Fund IV, L.P. ("RiverVest IV") are indirectly held by RiverVest Venture Partners IV, L.P. ("RiverVest Partners IV"), which is the general partner of RiverVest IV. RiverVest Venture Partners IV, LLC is the general partner of RiverVest Partners IV.
F3 The individual managers of RiverVest Ventures Partners IV, LLC are Jay Schmelter, John P. McKearn, Ph.D. and Niall O'Donnell. RiverVest Partners IV, RiverVest Venture Partners IV, LLC and each of the individual managers share voting and dispositive power with regard to the securities directly held by RiverVest Venture Fund IV, L.P.